HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy and tolerability of brodimoprim in otitis.

Abstract
Eighty adult patients affected by acute bacterial otitis media were selected and randomized into two balanced groups of treatment: 1) brodimoprim 200 mg tablets at the dosage of 2 tablets in single dose on the first day and one tablet on the following days; 2) josamycin 500 mg tablets at the dosage of 3 tablets/day. The average duration of treatment was 8 days: all patients completed the trial. The symptoms were evaluated by score method (on the 3rd, 7th and on the last day of therapy) and a thermometric curve was made daily. Microbiological examination of the exudate was performed in the patients with auricular discharge (28), at the beginning of the treatment and 7 days after the end of therapy. The tolerability was assessed through registration of side effects. Brodimoprim resulted more effective in the reduction of hypoacusis and tinnitus; other symptoms demonstrated higher percentage reductions in the group under brodimoprim therapy. Bacteriological exams were negative at the second checkup, except in 6 patients (3 per group). Side effects were reported in 5 patients (12.5%) treated with brodimoprim and in 9 (22.5%) treated with josamycin. Abnormal values in laboratory tests were not observed.
AuthorsE De Campora, M Radici, A Camaioni
JournalJournal of chemotherapy (Florence, Italy) (J Chemother) Vol. 5 Issue 6 Pg. 529-31 (Dec 1993) ISSN: 1120-009X [Print] England
PMID8195851 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Trimethoprim
  • Josamycin
  • brodimoprim
Topics
  • Acute Disease
  • Adolescent
  • Adult
  • Aged
  • Bacterial Infections
  • Drug Tolerance
  • Exudates and Transudates (microbiology)
  • Female
  • Humans
  • Josamycin (adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Otitis Media (drug therapy, microbiology)
  • Trimethoprim (analogs & derivatives, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: